for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before July 30, 2002, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Tara Turner at least 7 days in advance of the meeting.

FDA regrets that it was unable to publish this notice 15 days prior to the August 6 and 7, 2002, Antiviral Drugs Advisory Committee meeting. Because the agency believes there is some urgency to bring these issues to public discussion and qualified members of the Antiviral Drugs Advisory Committee were available at this time, the Commissioner of Food and Drugs concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: July 18, 2002.

William K. Hubbard,

Senior Associate Commissioner for Policy, Planning, and Legislation. [FR Doc. 02–18772 Filed 7–24–02; 8:45 am] BILLING CODE 4160–01–S

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Food and Drug Administration

# Food Biotechnology Subcommittee of the Food Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

#### ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committee*: Food Biotechnology Subcommittee of the Food Advisory Committee. General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on August 13, 2002, from 9 a.m. to 4:30 p.m. and August 14, 2002, from 9 a.m. to 4:30 p.m.

*Location*: Harvey W. Wiley Federal Bldg., 5100 Paint Branch Pkwy., College Park, MD 20740, 301–436–2200.

*Contact Person*: Margaret E. Cole, Center for Food Safety and Applied Nutrition (HFS–006), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301– 436–2397, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 10564. Please call the Information Line for up-to-date information on this meeting.

*Agenda*: The purpose of the meeting is to discuss science-based approaches to assessing whether new proteins in bioengineered foods are likely to cause allergic reactions in some individuals in order to assist FDA in developing a draft guidance for industry.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by July 30, 2002. Oral presentations from the public will be scheduled between approximately 10:15 a.m. and 11:30 a.m. on August 14, 2002. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before July 30, 2002, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Margaret E. Cole at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). Dated: July 18, 2002. William K. Hubbard, Senior Associate Commissioner for Policy, Planning, and Legislation. [FR Doc. 02–18773 Filed 7–24–02; 8:45 am] BILLING CODE 4160–01–S

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Food and Drug Administration

#### Ear, Nose, and Throat Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

#### **ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

*Name of Committee*: Ear, Nose, and Throat Devices Panel of the Medical Devices Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on August 16, 2002, from 10:30 a.m. to 4:30 p.m.

*Location*: Holiday Inn, Walker/ Whetstone Rooms, Two Montgomery Village Ave., Gaithersburg, MD.

*Contact Person*: Sara M. Thornton, Center for Devices and Radiological Health (HFZ–460), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–594–2053, ext. 127, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12522. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will discuss and make recommendations on a draft guidance entitled "Implantable Middle Ear Hearing Device; Draft Guidance for Industry and FDA." The topics for discussion will include the appropriate study population, objective measurement techniques for comparison of acoustic hearing aids and middle ear hearing devices, and subjective questionnaire development for determining postoperative effectiveness and quality of life outcome measures. The draft guidance is available to the public on the Internet at http:// www.fda.gov/cdrh/ode/guidance/ 1406.html.

Background information, including the attendee list, agenda, and questions for the committee, will be available to the public on August 15, 2002, on the Internet at http://www.fda.gov/cdrh/ panelmtg.html.

Procedure: On August 16, 2002, from 12:30 p.m. to 4:30 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by August 8, 2002. Oral presentations from the public will be scheduled between approximately 12:40 p.m. and 1:10 p.m. and 3:45 p.m. and 4:15 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before August 8, 2002, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

*Closed Committee Deliberations.* On August 16, 2002, from 10:30 a.m. to 12:30 p.m., the meeting will be closed to the public to permit discussion and review of trade secret and/or confidential information regarding pending issues and applications (5 U.S.C. 552b(c)(4)).

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Shirley Meeks, Conference Management Staff, at 301–594–1283, ext. 105, at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: July 18, 2002.

## William K. Hubbard,

Senior Associate Commissioner for Policy, Planning, and Legislation.

[FR Doc. 02–18774 Filed 7–24–02; 8:45 am]

BILLING CODE 4160-01-S

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Health Resources and Services Administration

### Demonstration Training Grants To Support Public Health Fellowships and Internships 93.249

**AGENCY:** Health Resources and Services Administration (HRSA). **ACTION:** Notice of availability of funds.

SUMMARY: The Health Resources and

Services Administration (HRSA) announces that Fiscal Year 2002 applications will be accepted to support one project under the Public Health Fellowship and Internship Demonstration Training Grant Program.

Authorizing Legislation: Applications are solicited under the authority of title VII, section 765 of the Public Health Service (PHS) Act, as amended. Section 765 authorizes the award of grants to increase the number of individuals in the public health workforce, to enhance the quality of such workforce, and to enhance the ability of the workforce to meet national, State, and local health care needs.

Purpose of Award: This Demonstration Training Grant is to support a program of innovative training and education opportunities to share expertise among public health faculty, fellow/interns, and health professionals at HRSA.

*Eligible Applicants:* An applicant must be: a health professions school (including an accredited school or program of public health, health administration, preventive medicine, or dental public health or a school providing health management programs), an academic health center, a State or local government, and any other appropriate public or private non-profit entity, including a faith-based and community based organization.

*Review Criteria:* The review criteria are: (1) Understanding of and approach to conducting a public health fellowship and internship program; (2) history of performance of applicant and its personnel; (3) adequacy of facilities and resources; (4) methods for achieving program objectives; (5) cost effectiveness; (6) national agency, and public health objectives, and (7) the ability to anticipate problems. Additional information pertaining to the review criteria will be listed in the supplement to instructions for application form HRSA 6025.

*Éstimated Amount of Available Funds:* It is anticipated that up to \$525,000 will be available in fiscal year 2002 for this program. *Estimated Number of Awards:* It is estimated that 1 award will be made for fiscal year 2002.

Application Requests, Availability, Dates and Addresses: The HRSA 6025 application kit will be available on July 25, 2002 and may be downloaded via the web at http://www.hrsa.gov/bhpr/ grants2002. The instructions for preparing the Public Health Fellowship and Internship Training Grant Applications are contained within application form HRSA 6025. Applicants may also request a hardcopy of the application material by contacting the HRSA Grants Application Center, 901 Russell Avenue, Suite 450, Gaithersburg, Maryland 20879, by fax calling at 1-877-477-2133, or by fax at 1-877-477-2345. In order to be considered for competition, applications must be received by mail or delivered to HRSA Grants Application Center by no later than August 26, 2002. Applications received after the deadline date may be returned to the applicant and not processed.

# FOR FURTHER INFORMATION CONTACT:

Douglas Lloyd, M.D., Acting Director, CPH, DSCPH, Bureau of Health Professions, HRSA, Room 8–103, Parklawn Building, 5600 Fishers Land, Rockville, Maryland 20857, or e-mail address *dlloyd@hrsa.gov*. Dr. Lloyd's telephone number is 301–443–6853. Capt. Barry Stern, Sr., Environmental Health Advisor, CPH, Bureau of Health Professions, HRSA, Room 8–103, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857; or e-mail address at *bstern@hrsa.gov*. Capt. Stern's telephone number is 301–443–6758.

Paperwork Reduction Act: The Application for the Public Health Fellowship and Internship Training Grant has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act. The OMB clearance number is 0915– 0060. The program is not subject to the provision of Executive Order 12372, Intergovernmental Review of Federal Programs (as implemented through 45 CFR part 100). This program is also not subject to the Public Health Systems Reporting Requirements.

Dated: July 18, 2002.

# Elizabeth M. Duke,

Administrator. [FR Doc. 02–18778 Filed 7–24–02; 8:45 am] BILLING CODE 4165–15–M

48666